The Role of Glucagon-Like Peptide-1 Receptor Agonists in Cognitive Decline and Dementia Prevention: A Systematic Review and Semiquantitative Synthesis. Journal of Mental Health and Human Behaviour , Aug
42 A phase 3 trial including adults with T2DM receiving orforglipron daily (3 mg, 12 mg or 36 mg) showed significant placebo-adjusted reductions in HbA 1c (1.07%) and weight loss (5.9%) at the highest dose
Clinical trials of Ozempic (semaglutide) have shown average A1C reductions of about 1.5% to 2.0%, while Mounjaro (tirzepatide) has demonstrated reductions of up to 2.4% in some studies
CMS is shooting for a 72-hour turnaround for prior authorization decisions
But the major limitation of the use of flavonoids is the adverse effects associated with their consumption in high doses, including necroptosis, apoptosis, cardiac dysfunction, and neurotoxic side effect (Satari et al., 2021)
Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 September 30, 2026) and incorporates current clinical practice standards from the Crohns & Colitis Foundation and the American College of Gastroenterology (ACG)
